The effect of Rho-associated kinase inhibition on the ocular penetration of timolol maleate

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 2, 2013, Pages 1118-1126

  Arnold, John J ^a   Hansen, Mark S ^b   Gorman, Gregory S ^a   Inoue, Toshihiro ^b   Rao, Vasantha ^b   Spellen, Simone ^a   Hunsinger, Ronald N ^a   Chapleau, Christopher A ^a,c   Pozzo Miller, Lucas ^c   Daniel Stamer, W ^b   Challa, Pratap ^b  

^a SAMFORD UNIVERSITY   (United States)

^b DUKE UNIVERSITY   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL) CYCLOHEXANECARBOXAMIDE; BRINZOLAMIDE; CD31 ANTIGEN; PHENYLEPHRINE; RHO KINASE; SOTALOL; TIMOLOL MALEATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; ARTICLE; CONFOCAL LASER MICROSCOPY; CONJUNCTIVA; CONTROLLED STUDY; CORNEA PERFORATION; IMMUNOHISTOCHEMISTRY; IRIS; LENS; MALE; MASS SPECTROMETRY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; SCANNING ELECTRON MICROSCOPY; SCLERA; SWINE; VASCULARIZATION; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; AMIDES; ANIMALS; ANTIGENS, CD31; AQUEOUS HUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; CONJUNCTIVA; CORNEA; DIFFUSION CHAMBERS, CULTURE; ENZYME INHIBITORS; IRIS; LENS, CRYSTALLINE; MALE; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; PYRIDINES; RABBITS; RHO-ASSOCIATED KINASES; SOTALOL; SULFONAMIDES; SWINE; TANDEM MASS SPECTROMETRY; THIAZINES; TIMOLOL; TISSUE DISTRIBUTION;

EID: 84874991488     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-10583     Document Type: Article

References (24)

1. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol. 2002;39:319-327.
2. Mohri M, Shimokawa H, Hirakawa Y, Masumoto A, Takeshita A. Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003;41:15-19.
3. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res. 2006;98:322-324.
4. Liao JK, Seto M, Noma K. Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol. 2007;50;17-24.
5. Mukai Y, Shimokawa H, Matoba T, et al. Involvement of Rhokinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J. 2001;15:1062-1064.
6. Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005;91:391-392.
7. Ying H, Biroc S, Li W-W, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther. 2006;5:2158-2164.
8. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Comm. 2000;269:652-659.
9. Mueller B, Mack H, Teusch N. Rho-kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005; 4:387-398.
10. Sugiyama T, Shibata M, Kajiura S, et al. Effects of fasudil, a rhoassociated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest Ophthalmol Vis Sci. 2011;52:64-69.
11. Rao V, Epstein D. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. Biodrugs. 2007;11:167-177.
12. Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rhoassociated protein kinase. Curr Eye Res. 2001;22:470-474.
13. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-44.
14. Tokushige H, Inatani M, Nemoto S, et al. Effects of topical administration of Y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits in monkeys. Invest Ophthalmol Vis Sci. 2007;48:3216-3222.
15. Williams RD, Novack GD, Van Haarlem T, Kopczynski C. Ocular hypotensive effect of the rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am J Ophthalmol. 2011;152:834-841.
16. Honjo M, Tanihara H, Inatani M, et al. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci. 2001;42:137-144.
17. Chen J, Runyan S, Robinson M. Novel ocular antihypertensive compounds in clinical trials. Clin Ophthalmol. 2011;5:667-677.
18. Lu Z, Overgy DR, Scott PA, Freddo TF, Gong H. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp Eye Res. 2008; 86:271-281.
19. Rao PV, Deng P-F, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci. 2001;42:1029-1037.
20. Rao PV, Deng P, Maddala R, Epstein D, Shimokawa H. Expression of dominant negative Rho-binding domain of Rho-kinase in organ cultured human eye anterior segments increases aqueous humor outflow. Mol Vis. 2005;11:288-297.
21. Hall A. Rho GTPases and actin cytoskeleton. Science. 1998; 279:509-514.
22. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of actin stress fibers and focal adhesions. J Cell Biol. 1996;133:1403-1415.
23. Kaibuchi K, Kuroda S, Amano M. Regulation of the cytoskeleton and cell adhesion by the Rho family GTPases in mammalian cells. Annu Rev Biochem. 1999;68:459-486.
24. J̈arvinen K, J̈arvinen T, Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev. 1995;16:3-19.